Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab)

Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC. Roche also presented monotherapy data for MPDL3280A in patients with mRCC who had been mostly pretreated.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news